Boston-based therapeutic video game developer Akili this week announced it is shifting focus from a prescription model to an over-the-counter (OTC) approach.
Why it's the BFD: Reimbursement for digital therapeutics has proved difficult to secure, with Akili rival Pear Therapeutics filing for bankruptcy in April.
